The 26 most recent market catalysts affecting $HCA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
The filing announces new analyst coverage for five companies, with all analysts initiating with bullish ratings (Outperform, Overweight, or Buy) and setting price targets significa…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On HCA Healthcare with Outperform Rating, Announces Price Target of $495
BMO Capital's initiation of coverage on HCA Healthcare with an 'Outperform' rating and a $495 price target is a significant development for the company. Analyst coverage, especiall…
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 55
Hyundai Auto Receivables Trust 2026-C Sells $2.07B Asset-Backed Notes
This 8-K filing details the completion of a securitization transaction by Hyundai Auto Receivables Trust 2026-C, where $2.066 billion in asset-backed notes were sold to underwriter…
Aug 20, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425
JP Morgan's analyst Benjamin Rossi maintained a 'Neutral' rating on HCA Healthcare, indicating no change in the fundamental outlook for the company from the bank's perspective. How…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $381
This filing discloses that Wells Fargo analyst Stephen Baxter has raised his price target for HCA Healthcare from $369 to $381, while maintaining an 'Equal-Weight' rating. This mat…
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on HCA Healthcare, Lowers Price Target to $475
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on HCA Healthcare, indicating a continued positive long-term outlook for the company. However, the price target was lower…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 75
Behind HCA's Q2 Beat: One-Time Medicaid Boost and a Growing Insurance Headwind
HCA Healthcare's Q2 earnings surpassed expectations, but analysts quickly pointed out that a substantial portion of this beat (around $400 million) came from incremental Medicaid s…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 65
Morgan Stanley Maintains Underweight on HCA Healthcare, Lowers Price Target to $380
Morgan Stanley analyst Craig Hettenbach maintained an 'Underweight' rating on HCA Healthcare and lowered the price target from $425 to $380. This action signals a more bearish stan…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 75
HCA Healthcare Analysts Slash Their Forecasts After Q2 Results
HCA Healthcare delivered a robust second quarter, surpassing both revenue and earnings consensus estimates for Q2 2026 and maintaining its full-year guidance. This would typically …
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on HCA Healthcare, Lowers Price Target to $495
Truist Securities, through analyst David Macdonald, has maintained its 'Buy' rating on HCA Healthcare but lowered the price target from $535 to $495. This adjustment, while still i…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Oppenheimer Maintains Outperform on HCA Healthcare, Lowers Price Target to $485
Oppenheimer analyst Michael Wiederhorn maintained an 'Outperform' rating on HCA Healthcare, signaling continued confidence in the company's long-term prospects. However, the reduct…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Keybanc Maintains Overweight on HCA Healthcare, Lowers Price Target to $435
Keybanc analyst Matthew Gillmor maintained an 'Overweight' rating on HCA Healthcare, signaling continued confidence in the company's long-term prospects. However, the price target …
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Baird Maintains Neutral on HCA Healthcare, Lowers Price Target to $393
Baird analyst Michael Ha reiterated a 'Neutral' rating on HCA Healthcare but made a slight downward revision to the price target, moving it from $396 to $393. This action indicates…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 75
Shares of medical device-related companies are trading higher following comments from HCA Healthcare on a conference call that business declines from uninsured patients didn't occur as expected in Q2, which is bullish for the medical device and equipment outlook following the end of ACA subsidies.
The headline indicates a significant positive shift in sentiment for the medical device and equipment sector. HCA Healthcare's comments suggest that patient volumes, particularly f…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 92
HCA Healthcare Surpasses Q2 Estimates With Strong Admissions Growth
HCA Healthcare's Q2 2026 earnings significantly beat analyst expectations, driven by an 8.7% year-over-year revenue increase and higher adjusted earnings. This positive performance…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 65
HCA Healthcare Exec Says Long-Term Patient Volume Growth Expected At 2%-3%, Supported By Market Demographics And Population Growth; Original Assumption Around Declining Utilization For Patients That Become Uninsured Due To The Loss Of Insurance Coverage Did Not Materialize
This 8-K filing discloses an HCA Healthcare executive's comments from a conference call, indicating an expectation of 2-3% long-term patient volume growth. This is significant beca…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
HCA Healthcare shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for HCA Healthcare, directly impacting its stock price positively due to strong financial performance. The better-than-exp…
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 55
HCA Healthcare Affirms FY2026 GAAP EPS Guidance of $28.70-$30.50 vs $29.70 Est; Affirms FY2026 Sales Guidance of $77.000B-$79.500B vs $78.457B Est
HCA Healthcare filed an 8-K to affirm its fiscal year 2026 GAAP EPS guidance of $28.70-$30.50 and sales guidance of $77.000 billion-$79.500 billion. This is a non-event in terms of…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 92
HCA Healthcare Q2 Adj. EPS $7.59 Beats $7.02 Estimate, Sales $20.230B Beat $19.400B Estimate
HCA Healthcare reported Q2 adjusted EPS of $7.59, beating the $7.02 consensus by 8.12%, and sales of $20.230 billion, exceeding the $19.400 billion estimate by 4.28%. This strong p…
Jul 15, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on HCA Healthcare, Lowers Price Target to $435
RBC Capital analyst Ben Hendrix maintained an 'Outperform' rating on HCA Healthcare, indicating a continued positive long-term outlook for the company. However, the significant red…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 75
Shares of healthcare services companies are trading lower amid sympathy with HCA Healthcare after that company lowered its FY26 GAAP EPS guidance.
HCA Healthcare's reduced FY26 GAAP EPS guidance signals potential challenges within the healthcare services sector, such as rising operating costs, reimbursement pressures, or slow…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 75
HCA Healthcare Narrows FY2026 Sales Guidance from $76.500B-$80.000B to $77.000B-$79.500B vs $78.643B Est
HCA Healthcare's 8-K filing indicates a narrowing of its fiscal year 2026 sales guidance. The previous range was $76.5 billion-$80.0 billion, and the new range is $77.0 billion-$79…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 55
Keybanc Maintains Overweight on HCA Healthcare, Lowers Price Target to $475
Keybanc analyst Matthew Gillmor maintained an 'Overweight' rating on HCA Healthcare, signaling continued confidence in the company's long-term prospects. However, the price target …
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 75
HCA Healthcare shares are trading lower after the company lowered its FY26 GAAP EPS guidance.
The lowered FY26 GAAP EPS guidance for HCA Healthcare is a direct negative corporate catalyst, indicating that the company anticipates lower future earnings than previously project…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 85
HCA Healthcare Reports Prelim Q2 Sales Of ~$20.230B, Up From $18.605B YoY; Lowers FY2026 GAAP EPS From $29.10-$31.50 To $28.70-$30.50
HCA Healthcare's preliminary Q2 2026 results show strong revenue growth year-over-year, but the core issue is the revised full-year 2026 guidance. The company significantly lowered…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
HCA Healthcare shares are trading lower after Wells Fargo maintained its Equal-Weight rating on the stock and lowered its price target from $436 to $428.
This headline represents a moderate corporate catalyst for HCA Healthcare. While an 'Equal-Weight' rating isn't a 'Sell', the lowered price target signals that Wells Fargo sees les…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.